{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,2,10]],"date-time":"2024-02-10T00:15:02Z","timestamp":1707524102275},"reference-count":16,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2020,6,18]]},"DOI":"10.7759\/cureus.8683","type":"journal-article","created":{"date-parts":[[2020,6,18]],"date-time":"2020-06-18T15:01:26Z","timestamp":1592492486000},"source":"Crossref","is-referenced-by-count":0,"title":["Radioiodine Therapy-Induced Conversion of Toxic Adenoma to Graves\u2019 Disease"],"prefix":"10.7759","author":[{"given":"Anis","family":"Rehman","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Silvana","family":"Obici","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Abid","family":"Yaqub","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1530\/EJE-16-0276","article-title":"Management of endocrine disease: subclinical thyrotoxicosis: prevalence, causes and choice of therapy","volume":"176","author":"Carl\u00e9 A","year":"2017","unstructured":"Carl\u00e9 A, Andersen SL, Boelaert K, Laurberg P. Management of endocrine disease: subclinical thyrotoxicosis: prevalence, causes and choice of therapy. Eur J Endocrinol. 2017, 176:325-337. 10.1530\/EJE-16-0276","journal-title":"Eur J Endocrinol"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1007\/s12026-012-8312-8","article-title":"Delineating the autoimmune mechanisms in Graves\u2019 disease","volume":"54","author":"Morshed SA","year":"2012","unstructured":"Morshed SA, Latif R, Davies TF. Delineating the autoimmune mechanisms in Graves\u2019 disease. Immunol Res. 2012, 54:191-203. 10.1007\/s12026-012-8312-8","journal-title":"Immunol Res"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2009-1719","article-title":"Increased circulating pro-inflammatory cytokines and Th17 lymphocytes in Hashimoto's thyroiditis","volume":"95","author":"Figueroa-Vega N","year":"2010","unstructured":"Figueroa-Vega N, Alfonso-P\u00e9rez M, Benedicto I, et al.. Increased circulating pro-inflammatory cytokines and Th17 lymphocytes in Hashimoto's thyroiditis. J Clin Endocrinol Metab. 2010, 95:953-962. 10.1210\/jc.2009-1719","journal-title":"J Clin Endocrinol Metab"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2016-2625","article-title":"ITM2A expands evidence for genetic and environmental interaction in Graves\u2019 disease pathogenesis","volume":"102","author":"Ye XP","year":"2017","unstructured":"Ye XP, Yuan FF, Zhang LL, et al.. ITM2A expands evidence for genetic and environmental interaction in Graves\u2019 disease pathogenesis. J Clin Endocrinol Metab. 2017, 102:652-660. 10.1210\/jc.2016-2625","journal-title":"J Clin Endocrinol Metab"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1210\/jcem.82.9.4227","article-title":"Thyrotropin receptor antibodies and Graves\u2019 disease, a side-effect of 131 I treatment in patients with nontoxic goiter","volume":"82","author":"Nygaard B","year":"1997","unstructured":"Nygaard B, Knudsen JH, Heqed\u00fcs L, et al.. Thyrotropin receptor antibodies and Graves\u2019 disease, a side-effect of 131 I treatment in patients with nontoxic goiter. J Clin Endocrinol Metab. 1997, 82:2926-2930. 10.1210\/jcem.82.9.4227","journal-title":"J Clin Endocrinol Metab"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2265.1995.tb01904.x","article-title":"Appearance of Graves\u2019-like disease after radioiodine therapy for toxic as well as non-toxic multinodular goitre","volume":"43","author":"Nygaard B","year":"1995","unstructured":"Nygaard B, Faber J, Veje A, Heqed\u00fcs L, Hansen JM. Appearance of Graves\u2019-like disease after radioiodine therapy for toxic as well as non-toxic multinodular goitre. Clin Endocrinol. 1995, 43:129-130. 10.1111\/j.1365-2265.1995.tb01904.x","journal-title":"Clin Endocrinol"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1089\/105072501753211091","article-title":"Development of Graves\u2019 hyperthyroidism after radioiodine treatment for a toxic nodule: is the hyperthyroidism always triggered by 1311 therapy?","volume":"11","author":"Niepomniszcze H","year":"2001","unstructured":"Niepomniszcze H, Pitoia F, Goodall C, Manavela M, Bruno OD. Development of Graves\u2019 hyperthyroidism after radioiodine treatment for a toxic nodule: is the hyperthyroidism always triggered by 1311 therapy?. Thyroid. 2001, 11:991. 10.1089\/105072501753211091","journal-title":"Thyroid"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1089\/thy.1999.9.477","article-title":"Transition of nodular toxic goiter to autoimmune hyperthyroidism trigged by 131I therapy","volume":"9","author":"Nygaard B","year":"1999","unstructured":"Nygaard B, Faber J, Veje A, Heqed\u00fcs L, Hansen JM. Transition of nodular toxic goiter to autoimmune hyperthyroidism trigged by 131I therapy. Thyroid. 1999, 9:477-481. 10.1089\/thy.1999.9.477","journal-title":"Thyroid"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1016\/s0300-2977(00)00068-1","article-title":"Graves' disease induced by Na(131) therapy for toxic multinodular goitre","volume":"57","author":"Van Leussen JJ","year":"2000","unstructured":"Van Leussen JJ, Edelbroek MA, Talsma MA, de Heide LJ. Graves' disease induced by Na(131) therapy for toxic multinodular goitre. Neth J Med. 2000, 57:194-197. 10.1016\/s0300-2977(00)00068-1","journal-title":"Neth J Med"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1089\/thy.2006.16.281","article-title":"Incidence of postradioiodine immunogenic hyperthyroidism\/Graves\u2019 disease in relation to a temporary increase in thyrotropin receptor antibodies after radioiodine therapy for autonomous thyroid disease","volume":"16","author":"Schmidt M","year":"2006","unstructured":"Schmidt M, Gorbauch E, Dietlein M, et al.. Incidence of postradioiodine immunogenic hyperthyroidism\/Graves\u2019 disease in relation to a temporary increase in thyrotropin receptor antibodies after radioiodine therapy for autonomous thyroid disease. Thyroid. 2006, 16:281-288. 10.1089\/thy.2006.16.281","journal-title":"Thyroid"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1089\/thy.1997.7.535","article-title":"Autoimmune hyperthyroidism occuring late after radioiodine treatment for volume reduction of large multinodular goiters","volume":"7","author":"Huysmans AK","year":"1997","unstructured":"Huysmans AK, Hermus RM, Edelbroek MA, et al.. Autoimmune hyperthyroidism occuring late after radioiodine treatment for volume reduction of large multinodular goiters. Thyroid. 1997, 7:535-539. 10.1089\/thy.1997.7.535","journal-title":"Thyroid"},{"key":"ref12","article-title":"Immunogenic hyperthyroidism following radioiodine ablation of focal autonomy","volume":"32","author":"Boddenberg B","year":"1993","unstructured":"Boddenberg B, Voth E, Schicha H. Immunogenic hyperthyroidism following radioiodine ablation of focal autonomy. Nuklearmedizin. 1993, 32:18-22.","journal-title":"Nuklearmedizin"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.4274\/mirt.74046","article-title":"Graves\u2019 disease induced by radioiodine therapy for toxic nodular goiter: a case report","volume":"24","author":"Y\u00fcrekli Y","year":"2015","unstructured":"Y\u00fcrekli Y, Cengiz A, G\u00fcney E. Graves\u2019 disease induced by radioiodine therapy for toxic nodular goiter: a case report. Mol Imaging Radionucl Ther. 2015, 24:135-137. 10.4274\/mirt.74046","journal-title":"Mol Imaging Radionucl Ther"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1007\/s40618-018-0827-y","article-title":"131 I-Induced Graves' disease in patients treated for toxic multinodular goitre: systematic review and descriptive analysis","volume":"41","author":"Roque C","year":"2018","unstructured":"Roque C, Vasconcelos CA. 131 I-Induced Graves' disease in patients treated for toxic multinodular goitre: systematic review and descriptive analysis. J Endocrinol Invest. 2018, 41:1019-1028. 10.1007\/s40618-018-0827-y","journal-title":"J Endocrinol Invest"},{"key":"ref15","article-title":"Pathological anatomy of exophthalmic goiter","volume":"8","author":"Marine D","year":"1911","unstructured":"Marine D, Lenhart CH. Pathological anatomy of exophthalmic goiter. Arch Intern Med. 1911, 8:265-316.","journal-title":"Arch Intern Med"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1530\/acta.0.1260416","article-title":"Evidence of intrathyroidal accumulation of TSH receptor antibody in Graves' disease","volume":"126","author":"Sugenoya A","year":"1992","unstructured":"Sugenoya A, Kobayashi S, Kasuga Y, et al.. Evidence of intrathyroidal accumulation of TSH receptor antibody in Graves' disease. Acta Endocrinol (Copenh). 1992, 126:416-418. 10.1530\/acta.0.1260416","journal-title":"Acta Endocrinol (Copenh)"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/26943-radioiodine-therapy-induced-conversion-of-toxic-adenoma-to-graves-disease","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,9]],"date-time":"2024-02-09T19:26:38Z","timestamp":1707506798000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/26943-radioiodine-therapy-induced-conversion-of-toxic-adenoma-to-graves-disease"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,6,18]]},"references-count":16,"URL":"https:\/\/doi.org\/10.7759\/cureus.8683","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2020,6,18]]}}}